|
|
 Previous Article | Table of Contents | Next Article 
Effects of recombinant human interleukin-3 on CD34-enriched normal
hematopoietic progenitors and on myeloblastic leukemia cells
S Saeland, C Caux, C Favre, JP Aubry, P Mannoni, MJ Pebusque, O Gentilhomme, T Otsuka, T Yokota and N Arai
UNICET Laboratory for Immunological Research, Dardilly, France.
Induction of proliferation and differentiation in response to recombinant
human interleukin-3 (hIL-3) was studied in liquid and semisolid cultures of
umbilical cord blood and bone marrow cells that were fractionated by
"panning" with anti-My10 antibody according to expression of CD34 antigen.
Cells from enriched fractions (70% to 90% CD34+) were found to proliferate
strongly in response to hIL-3. Phenotypic analysis and morphologic
characterization of the proliferating cells demonstrated a rapid decrease
in CD34+ cells and an exponential increase in the number of cells belonging
to the neutrophilic, eosinophilic, monocyte/macrophage, and thrombocytic
lineages. When combined with recombinant human erythropoietin, burst
colonies and cells expressing glycophorin-A were detected, thereby
demonstrating the effects of hIL-3 on erythroid progenitors. Further, the
development of mixed-erythroid colonies indicated that multipotential cells
within CD34-enriched fractions responded to hIL-3. In addition, we examined
the effect of hIL-3 on the proliferation of primary acute myeloblastic
leukemia cells in liquid culture. We found that hIL-3 was able to induce
cell proliferation in a proportion of the cases tested. Heterogeneity of
the responses to hIL-3 was in part related to French-American-British
classification but could not be correlated with CD34 antigen expression by
the leukemic cells. These results indicate that, although the effects of
hIL-3 on proliferation and differentiation of cells obtained from normal
hematopoietic specimens were primarily borne by CD34+ cells, expression of
the CD34 molecule per se is an insufficient condition to determine a growth
response to this lymphokine.
Volume 72,
Issue 5,
pp. 1580-1588,
11/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Eder, G. Geissler, and A. Ganser
IL-3 in the Clinic
Stem Cells,
September 1, 1997;
15(5):
327 - 333.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
U. Junker, J. J. Moon, C. S. Kalfoglou, I. Sniecinski, S. J. Forman, J. A. Zaia, H. Kaneshima, and E. Bohnlein
Hematopoietic Potential and Retroviral Transduction of CD34+Thy-1+ Peripheral Blood Stem Cells From Asymptomatic Human Immunodeficiency Virus Type-1-Infected Individuals Mobilized With Granulocyte Colony-Stimulating Factor
Blood,
June 15, 1997;
89(12):
4299 - 4306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Schwartz, M. Warren, K Sakano, J. Szabo, S. Kessler, A Pashapour, R. Gress, and J. Perdue
Comparative effects of insulin-like growth factor II (IGF-II) and IGF- II mutants specific for IGF-II/CIM6-P or IGF-I receptors on in vitro hematopoiesis
Stem Cells,
May 1, 1996;
14(3):
337 - 350.
[Abstract]
|
|
|
|
|
